Evidence map›Paper›PMID 32894370›Full record

ReviewCancer metastasis reviews2020

Gastric cancer: a comprehensive review of current and future treatment strategies.

Rachel E Sexton, Mohammed Najeeb Al Hallak, Maria Diab, Asfar S Azmi

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer metastasis reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05699278 (An Observational Study Evaluating The Experiences of Gastric Cancer Patients In Clinical Trials), which is not on this map. Cited by 480 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05699278 unknown statusnot on this mapstarted 2024, after this paper: background citation

An Observational Study Evaluating The Experiences of Gastric Cancer Patients In Clinical Trials

TypeobservationalSponsorPower Life Sciences Inc.Ran2024 to 2026Enrolled500ConditionsGastric Cancer
3 · Its place in the literature

Who cites it

480 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Implementation ofJCO precision oncology · 2025
    Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

420 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rachel E SextonDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI, 48201, USA.
Mohammed Najeeb Al HallakDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI, 48201, USA.
Maria DiabDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI, 48201, USA.
Asfar S AzmiDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI, 48201, USA. azmia@karmanos.org.ORCID 0000-0003-1178-9505

Funding

Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic CancerR37CA215427 · NCI · WAYNE STATE UNIVERSITY · PI AZMI, ASFAR S · 2018 to 2024
$2.4M
NCI NIH HHS R37 CA215427
6 · The paper itself

Abstract

Gastric cancer remains a major unmet clinical problem with over 1 million new cases worldwide. It is the fourth most commonly occurring cancer in men and the seventh most commonly occurring cancer in women. A major fraction of gastric cancer has been linked to variety of pathogenic infections including but not limited to Helicobacter pylori (H. pylori) or Epstein Barr virus (EBV). Strategies are being pursued to prevent gastric cancer development such as H. pylori eradication, which has helped to prevent significant proportion of gastric cancer. Today, treatments have helped to manage this disease and the 5-year survival for stage IA and IB tumors treated with surgery are between 60 and 80%. However, patients with stage III tumors undergoing surgery have a dismal 5-year survival rate between 18 and 50% depending on the dataset. These figures indicate the need for more effective molecularly driven treatment strategies. This review discusses the molecular profile of gastric tumors, the success, and challenges with available therapeutic targets along with newer biomarkers and emerging targets.

Indexed as

AnimalsBiomarkers, TumorClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyEpstein-Barr Virus InfectionsHelicobacter InfectionsHelicobacter pyloriHerpesvirus 4, HumanHumansMolecular Targeted TherapyNeoplasm StagingRandomized Controlled Trials as TopicStomach NeoplasmsBiomarkers, TumorAutophagyGastric adenocarcinomaGastric cancerlncRNANon coding RNAsNovel targetsPiwi RNA

Identifiers

PMID32894370
PMCPMC7680370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.